Your browser doesn't support javascript.
loading
Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma.
Zhang, Huilai; Dong, Ling; Chen, Qingqing; Kong, Lingzhe; Meng, Bin; Wang, Huaqing; Fu, Kai; Wang, Xi; Pan-Hammarström, Qiang; Wang, Ping; Wang, Xianhuo.
Affiliation
  • Zhang H; Department of Lymphoma, Department of Pathology and Department of Radiotherapy, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Researc
  • Dong L; Department of Lymphoma, Department of Pathology and Department of Radiotherapy, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Researc
  • Chen Q; Department of Lymphoma, Department of Pathology and Department of Radiotherapy, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Researc
  • Kong L; Department of Lymphoma, Department of Pathology and Department of Radiotherapy, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Researc
  • Meng B; Department of Lymphoma, Department of Pathology and Department of Radiotherapy, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Researc
  • Wang H; Department of Oncology, Tianjin Union Medicine Center, Tianjin, China.
  • Fu K; Department of Lymphoma, Department of Pathology and Department of Radiotherapy, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Researc
  • Wang X; Department of Cellular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
  • Pan-Hammarström Q; Department of Lymphoma, Department of Pathology and Department of Radiotherapy, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Researc
  • Wang P; Department of Lymphoma, Department of Pathology and Department of Radiotherapy, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Researc
  • Wang X; Department of Lymphoma, Department of Pathology and Department of Radiotherapy, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Researc
Leuk Res ; 56: 29-35, 2017 05.
Article in En | MEDLINE | ID: mdl-28171799

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Doxorubicin / Lymphoma, T-Cell, Peripheral / Histone Deacetylase Inhibitors Limits: Humans Language: En Journal: Leuk Res Year: 2017 Document type: Article Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Doxorubicin / Lymphoma, T-Cell, Peripheral / Histone Deacetylase Inhibitors Limits: Humans Language: En Journal: Leuk Res Year: 2017 Document type: Article Country of publication: United kingdom